Share

Quality of Life in Oncology Resource Centre

To optimize quality of life in oncology patients preventive measures to avoid occurrence of adverse effects of the disease and its treatment are required. Where prevention is not feasible, proper management to minimize both physical and psychological adverse effects is needed. By maximizing the patient’s quality of life patient resilience is enhanced, supporting acceptance, rehabilitation, compliance and generally easing the significant emotional burden of both patients and care givers. Therefore, supportive care designed to uphold the quality of life of patients and those directly involved by preventing and alleviating the symptoms and complications of cancer (treatment) is essential to allow maximal benefit of the treatment options at hand.

Elsevier has launched a Quality of Life in Oncology Resource Centre providing free full-text access to peer-reviewed original research and review articles on the quality of life during all disease stages of cancer – from diagnosis to post-diagnostic care, as well as interviews with leading experts, links to guidelines on Supportive and Palliative Care in Cancer, clinical and teaching cases and podcasts and News updates from oncology conferences.
The editor-in-chief of the resource centre is  Dr. Matti S. Aapro (Multidisciplinary Institute of Oncology, Genolier, Switzerland). The resource centre is supported by an international Editorial board of experts: Dr Florian Scotté (France) Dr Carla Ripamonti (Italy), Dr Ricardo Caponero (Brazil), Dr Anton Snegovoy (Russia) and Dr Martin Chasen (USA).
The Quality of Life in Oncology resource centre is supported by an educational grant from Helsinn and the company does not have any influence on the content and all items are subject to independent peer and editorial review.

Elsevier

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023